[1]
Vlachou E, Owens DA, Lavdaniti M, Kalemikerakis J, Evagelou E, Margari N, Fasoi G, Evangelidou E, Govina O, Tsartsalis AN. Prevalence, Wellbeing, and Symptoms of Dysmenorrhea among University Nursing Students in Greece. Diseases (Basel, Switzerland). 2019 Jan 8:7(1):. doi: 10.3390/diseases7010005. Epub 2019 Jan 8
[PubMed PMID: 30626091]
[2]
Burnett M, Lemyre M. No. 345-Primary Dysmenorrhea Consensus Guideline. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC. 2017 Jul:39(7):585-595. doi: 10.1016/j.jogc.2016.12.023. Epub
[PubMed PMID: 28625286]
Level 3 (low-level) evidence
[4]
Chauhan M, Kala J. Relation between dysmenorrhea and body mass index in adolescents with rural versus urban variation. Journal of obstetrics and gynaecology of India. 2012 Aug:62(4):442-5. doi: 10.1007/s13224-012-0171-7. Epub 2012 Jun 1
[PubMed PMID: 23904707]
[5]
Kho KA, Shields JK. Diagnosis and Management of Primary Dysmenorrhea. JAMA. 2020 Jan 21:323(3):268-269. doi: 10.1001/jama.2019.16921. Epub
[PubMed PMID: 31855238]
[6]
Ferries-Rowe E, Corey E, Archer JS. Primary Dysmenorrhea: Diagnosis and Therapy. Obstetrics and gynecology. 2020 Nov:136(5):1047-1058. doi: 10.1097/AOG.0000000000004096. Epub
[PubMed PMID: 33030880]
[7]
Zebitay AG, Verit FF, Sakar MN, Keskin S, Cetin O, Ulusoy AI. Importance of cervical length in dysmenorrhoea aetiology. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2016 May:36(4):540-3. doi: 10.3109/01443615.2015.1127901. Epub 2016 Mar 25
[PubMed PMID: 27012227]
[8]
Dawood MY. Current concepts in the etiology and treatment of primary dysmenorrhea. Acta obstetricia et gynecologica Scandinavica. Supplement. 1986:138():7-10
[PubMed PMID: 3548208]
[9]
Qin LL, Hu Z, Kaminga AC, Luo BA, Xu HL, Feng XL, Liu JH. Association between cigarette smoking and the risk of dysmenorrhea: A meta-analysis of observational studies. PloS one. 2020:15(4):e0231201. doi: 10.1371/journal.pone.0231201. Epub 2020 Apr 15
[PubMed PMID: 32294123]
Level 1 (high-level) evidence
[10]
Ju H, Jones M, Mishra G. The prevalence and risk factors of dysmenorrhea. Epidemiologic reviews. 2014:36():104-13. doi: 10.1093/epirev/mxt009. Epub 2013 Nov 26
[PubMed PMID: 24284871]
[11]
Proctor M, Farquhar C. Diagnosis and management of dysmenorrhoea. BMJ (Clinical research ed.). 2006 May 13:332(7550):1134-8
[PubMed PMID: 16690671]
[12]
Lundström V, Gréen K, Svanborg K. Endogenous prostaglandins in dysmenorrhea and the effect of prostaglandin synthetase inhibitors (PGSI) on uterine contractility. Acta obstetricia et gynecologica Scandinavica. Supplement. 1979:87():51-6
[PubMed PMID: 111466]
[14]
Ylikorkala O, Dawood MY. New concepts in dysmenorrhea. American journal of obstetrics and gynecology. 1978 Apr 1:130(7):833-47
[PubMed PMID: 25021]
[15]
Mrugacz G, Grygoruk C, Sieczyński P, Grusza M, Bołkun I, Pietrewicz P. [Etiopathogenesis of dysmenorrhea]. Medycyna wieku rozwojowego. 2013 Jan-Mar:17(1):85-9
[PubMed PMID: 23749700]
[16]
Budny-Winska J, Pomorski M. Uterine niche after cesarean section: a review of diagnostic methods. Ginekologia polska. 2021:92(10):726-730. doi: 10.5603/GP.a2021.0195. Epub
[PubMed PMID: 34747000]
[17]
Oladosu FA, Tu FF, Hellman KM. Nonsteroidal antiinflammatory drug resistance in dysmenorrhea: epidemiology, causes, and treatment. American journal of obstetrics and gynecology. 2018 Apr:218(4):390-400. doi: 10.1016/j.ajog.2017.08.108. Epub 2017 Sep 6
[PubMed PMID: 28888592]
[18]
Agarwal AK, Agarwal A. A study of dysmenorrhea during menstruation in adolescent girls. Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine. 2010 Jan:35(1):159-64. doi: 10.4103/0970-0218.62586. Epub
[PubMed PMID: 20606943]
[19]
Alsaleem MA. Dysmenorrhea, associated symptoms, and management among students at King Khalid University, Saudi Arabia: An exploratory study. Journal of family medicine and primary care. 2018 Jul-Aug:7(4):769-774. doi: 10.4103/jfmpc.jfmpc_113_18. Epub
[PubMed PMID: 30234051]
[20]
Zannoni L, Giorgi M, Spagnolo E, Montanari G, Villa G, Seracchioli R. Dysmenorrhea, absenteeism from school, and symptoms suspicious for endometriosis in adolescents. Journal of pediatric and adolescent gynecology. 2014 Oct:27(5):258-65. doi: 10.1016/j.jpag.2013.11.008. Epub 2014 Apr 18
[PubMed PMID: 24746919]
[21]
Word RA, Kamm KE, Casey ML. Contractile effects of prostaglandins, oxytocin, and endothelin-1 in human myometrium in vitro: refractoriness of myometrial tissue of pregnant women to prostaglandins E2 and F2 alpha. The Journal of clinical endocrinology and metabolism. 1992 Oct:75(4):1027-32
[PubMed PMID: 1400867]
Level 3 (low-level) evidence
[22]
Ekström P, Akerlund M, Forsling M, Kindahl H, Laudanski T, Mrugacz G. Stimulation of vasopressin release in women with primary dysmenorrhoea and after oral contraceptive treatment--effect on uterine contractility. British journal of obstetrics and gynaecology. 1992 Aug:99(8):680-4
[PubMed PMID: 1390475]
[23]
Bernardi M, Lazzeri L, Perelli F, Reis FM, Petraglia F. Dysmenorrhea and related disorders. F1000Research. 2017:6():1645. doi: 10.12688/f1000research.11682.1. Epub 2017 Sep 5
[PubMed PMID: 28944048]
[24]
Falcone T, Flyckt R. Clinical Management of Endometriosis. Obstetrics and gynecology. 2018 Mar:131(3):557-571. doi: 10.1097/AOG.0000000000002469. Epub
[PubMed PMID: 29420391]
[25]
Agarwal SK, Chapron C, Giudice LC, Laufer MR, Leyland N, Missmer SA, Singh SS, Taylor HS. Clinical diagnosis of endometriosis: a call to action. American journal of obstetrics and gynecology. 2019 Apr:220(4):354.e1-354.e12. doi: 10.1016/j.ajog.2018.12.039. Epub 2019 Jan 6
[PubMed PMID: 30625295]
[26]
Osayande AS, Mehulic S. Diagnosis and initial management of dysmenorrhea. American family physician. 2014 Mar 1:89(5):341-6
[PubMed PMID: 24695505]
[27]
Akin MD, Weingand KW, Hengehold DA, Goodale MB, Hinkle RT, Smith RP. Continuous low-level topical heat in the treatment of dysmenorrhea. Obstetrics and gynecology. 2001 Mar:97(3):343-9
[PubMed PMID: 11239634]
[28]
Akin M, Price W, Rodriguez G Jr, Erasala G, Hurley G, Smith RP. Continuous, low-level, topical heat wrap therapy as compared to acetaminophen for primary dysmenorrhea. The Journal of reproductive medicine. 2004 Sep:49(9):739-45
[PubMed PMID: 15493566]
[29]
Matthewman G, Lee A, Kaur JG, Daley AJ. Physical activity for primary dysmenorrhea: a systematic review and meta-analysis of randomized controlled trials. American journal of obstetrics and gynecology. 2018 Sep:219(3):255.e1-255.e20. doi: 10.1016/j.ajog.2018.04.001. Epub 2018 Apr 7
[PubMed PMID: 29630882]
Level 1 (high-level) evidence
[30]
Hosseinlou A, Alinejad V, Alinejad M, Aghakhani N. The effects of fish oil capsules and vitamin B1 tablets on duration and severity of dysmenorrhea in students of high school in Urmia-Iran. Global journal of health science. 2014 Sep 18:6(7 Spec No):124-9. doi: 10.5539/gjhs.v6n7p124. Epub 2014 Sep 18
[PubMed PMID: 25363189]
[31]
Barnard ND, Scialli AR, Hurlock D, Bertron P. Diet and sex-hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstetrics and gynecology. 2000 Feb:95(2):245-50
[PubMed PMID: 10674588]
[32]
Abdul-Razzak KK, Ayoub NM, Abu-Taleb AA, Obeidat BA. Influence of dietary intake of dairy products on dysmenorrhea. The journal of obstetrics and gynaecology research. 2010 Apr:36(2):377-83. doi: 10.1111/j.1447-0756.2009.01159.x. Epub
[PubMed PMID: 20492391]
[33]
Wilson ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Nursing times. 2001 Sep 6-12:97(36):44
[PubMed PMID: 11957721]
[34]
Côté P, Hartvigsen J, Axén I, Leboeuf-Yde C, Corso M, Shearer H, Wong J, Marchand AA, Cassidy JD, French S, Kawchuk GN, Mior S, Poulsen E, Srbely J, Ammendolia C, Blanchette MA, Busse JW, Bussières A, Cancelliere C, Christensen HW, De Carvalho D, De Luca K, Du Rose A, Eklund A, Engel R, Goncalves G, Hebert J, Hincapié CA, Hondras M, Kimpton A, Lauridsen HH, Innes S, Meyer AL, Newell D, O'Neill S, Pagé I, Passmore S, Perle SM, Quon J, Rezai M, Stupar M, Swain M, Vitiello A, Weber K, Young KJ, Yu H. The global summit on the efficacy and effectiveness of spinal manipulative therapy for the prevention and treatment of non-musculoskeletal disorders: a systematic review of the literature. Chiropractic & manual therapies. 2021 Feb 17:29(1):8. doi: 10.1186/s12998-021-00362-9. Epub 2021 Feb 17
[PubMed PMID: 33596925]
Level 1 (high-level) evidence
[35]
Witt CM, Reinhold T, Brinkhaus B, Roll S, Jena S, Willich SN. Acupuncture in patients with dysmenorrhea: a randomized study on clinical effectiveness and cost-effectiveness in usual care. American journal of obstetrics and gynecology. 2008 Feb:198(2):166.e1-8. doi: 10.1016/j.ajog.2007.07.041. Epub
[PubMed PMID: 18226614]
Level 1 (high-level) evidence
[36]
Helms JM. Acupuncture for the management of primary dysmenorrhea. Obstetrics and gynecology. 1987 Jan:69(1):51-6
[PubMed PMID: 3540764]
[37]
Shetty GB, Shetty B, Mooventhan A. Efficacy of Acupuncture in the Management of Primary Dysmenorrhea: A Randomized Controlled Trial. Journal of acupuncture and meridian studies. 2018 Aug:11(4):153-158. doi: 10.1016/j.jams.2018.04.001. Epub 2018 Apr 12
[PubMed PMID: 29654840]
Level 1 (high-level) evidence
[38]
Doty E, Attaran M. Managing primary dysmenorrhea. Journal of pediatric and adolescent gynecology. 2006 Oct:19(5):341-4
[PubMed PMID: 17060018]
[40]
Marjoribanks J, Proctor M, Farquhar C, Derks RS. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. The Cochrane database of systematic reviews. 2010 Jan 20:(1):CD001751. doi: 10.1002/14651858.CD001751.pub2. Epub 2010 Jan 20
[PubMed PMID: 20091521]
Level 1 (high-level) evidence
[41]
Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. American journal of obstetrics and gynecology. 1984 Jan 1:148(1):96-103
[PubMed PMID: 6419611]
[42]
Budoff PW. Use of mefenamic acid in the treatment of primary dysmenorrhea. JAMA. 1979 Jun 22:241(25):2713-6
[PubMed PMID: 376875]
[43]
Milsom I, Minic M, Dawood MY, Akin MD, Spann J, Niland NF, Squire RA. Comparison of the efficacy and safety of nonprescription doses of naproxen and naproxen sodium with ibuprofen, acetaminophen, and placebo in the treatment of primary dysmenorrhea: a pooled analysis of five studies. Clinical therapeutics. 2002 Sep:24(9):1384-400
[PubMed PMID: 12380631]
[44]
Feng X, Wang X. Comparison of the efficacy and safety of non-steroidal anti-inflammatory drugs for patients with primary dysmenorrhea: A network meta-analysis. Molecular pain. 2018 Jan-Dec:14():1744806918770320. doi: 10.1177/1744806918770320. Epub 2018 Mar 27
[PubMed PMID: 29587566]
Level 1 (high-level) evidence
[45]
Harel Z. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea. Journal of pediatric and adolescent gynecology. 2004 Apr:17(2):75-9
[PubMed PMID: 15050982]
[46]
Pall M, Fridén BE, Brännström M. Induction of delayed follicular rupture in the human by the selective COX-2 inhibitor rofecoxib: a randomized double-blind study. Human reproduction (Oxford, England). 2001 Jul:16(7):1323-8
[PubMed PMID: 11425807]
Level 1 (high-level) evidence
[47]
Bata MS, Al-Ramahi M, Salhab AS, Gharaibeh MN, Schwartz J. Delay of ovulation by meloxicam in healthy cycling volunteers: A placebo-controlled, double-blind, crossover study. Journal of clinical pharmacology. 2006 Aug:46(8):925-32
[PubMed PMID: 16855077]
Level 1 (high-level) evidence
[48]
Armour M, Parry K, Al-Dabbas MA, Curry C, Holmes K, MacMillan F, Ferfolja T, Smith CA. Self-care strategies and sources of knowledge on menstruation in 12,526 young women with dysmenorrhea: A systematic review and meta-analysis. PloS one. 2019:14(7):e0220103. doi: 10.1371/journal.pone.0220103. Epub 2019 Jul 24
[PubMed PMID: 31339951]
Level 1 (high-level) evidence
[49]
Ali Z, Burnett I, Eccles R, North M, Jawad M, Jawad S, Clarke G, Milsom I. Efficacy of a paracetamol and caffeine combination in the treatment of the key symptoms of primary dysmenorrhoea. Current medical research and opinion. 2007 Apr:23(4):841-51
[PubMed PMID: 17407641]
Level 3 (low-level) evidence
[50]
Di Girolamo G, Sánchez AJ, De Los Santos AR, González CD. Is acetaminophen, and its combination with pamabrom, an effective therapeutic option in primary dysmenorrhoea? Expert opinion on pharmacotherapy. 2004 Mar:5(3):561-70
[PubMed PMID: 15013925]
Level 3 (low-level) evidence
[52]
Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, Creasy GW, ORTHO EVRA/EVRA 004 Study Group. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs an oral contraceptive: a randomized controlled trial. JAMA. 2001 May 9:285(18):2347-54
[PubMed PMID: 11343482]
Level 1 (high-level) evidence
[53]
Petraglia F, Parke S, Serrani M, Mellinger U, Römer T. Estradiol valerate plus dienogest versus ethinylestradiol plus levonorgestrel for the treatment of primary dysmenorrhea. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 2014 Jun:125(3):270-4. doi: 10.1016/j.ijgo.2013.11.017. Epub 2014 Mar 11
[PubMed PMID: 24713413]
[54]
Callejo J, Díaz J, Ruiz A, García RM. Effect of a low-dose oral contraceptive containing 20 microg ethinylestradiol and 150 microg desogestrel on dysmenorrhea. Contraception. 2003 Sep:68(3):183-8
[PubMed PMID: 14561538]
[55]
Wong CL, Farquhar C, Roberts H, Proctor M. Oral contraceptive pill as treatment for primary dysmenorrhoea. The Cochrane database of systematic reviews. 2009 Apr 15:(2):CD002120. doi: 10.1002/14651858.CD002120.pub2. Epub 2009 Apr 15
[PubMed PMID: 19370576]
Level 1 (high-level) evidence
[56]
Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. The Cochrane database of systematic reviews. 2001:(4):CD002120
[PubMed PMID: 11687142]
Level 1 (high-level) evidence
[57]
Casper RF. Progestin-only pills may be a better first-line treatment for endometriosis than combined estrogen-progestin contraceptive pills. Fertility and sterility. 2017 Mar:107(3):533-536. doi: 10.1016/j.fertnstert.2017.01.003. Epub 2017 Feb 2
[PubMed PMID: 28162779]
[58]
Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. European journal of obstetrics, gynecology, and reproductive biology. 2010 Aug:151(2):193-8. doi: 10.1016/j.ejogrb.2010.04.002. Epub 2010 May 5
[PubMed PMID: 20444534]
Level 1 (high-level) evidence
[59]
Al-Jefout M, Nawaiseh N. Continuous Norethisterone Acetate versus Cyclical Drospirenone 3 mg/Ethinyl Estradiol 20 μg for the Management of Primary Dysmenorrhea in Young Adult Women. Journal of pediatric and adolescent gynecology. 2016 Apr:29(2):143-7. doi: 10.1016/j.jpag.2015.08.009. Epub 2015 Sep 3
[PubMed PMID: 26342733]
[60]
Smorgick N, As-Sanie S. Pelvic Pain in Adolescents. Seminars in reproductive medicine. 2018 Mar:36(2):116-122. doi: 10.1055/s-0038-1676088. Epub 2018 Dec 19
[PubMed PMID: 30566977]
[61]
Marin L, Andrisani A, Buzzaccarini G, Capobianco G, Dessole F, Chiantera V, Laganà AS, Ambrosini G. Membranous dysmenorrhoea in a woman undergoing hormone replacement preparation for embryo transfer - a peculiar case. Przeglad menopauzalny = Menopause review. 2023 Mar:22(1):55-57. doi: 10.5114/pm.2023.126388. Epub 2023 Mar 31
[PubMed PMID: 37206679]
Level 3 (low-level) evidence
[62]
Habibi N, Huang MS, Gan WY, Zulida R, Safavi SM. Prevalence of Primary Dysmenorrhea and Factors Associated with Its Intensity Among Undergraduate Students: A Cross-Sectional Study. Pain management nursing : official journal of the American Society of Pain Management Nurses. 2015 Dec:16(6):855-61. doi: 10.1016/j.pmn.2015.07.001. Epub 2015 Aug 29
[PubMed PMID: 26328887]
Level 2 (mid-level) evidence
[63]
Femi-Agboola DM, Sekoni OO, Goodman OO. Dysmenorrhea and Its Effects on School Absenteeism and School Activities among Adolescents in Selected Secondary Schools in Ibadan, Nigeria. Nigerian medical journal : journal of the Nigeria Medical Association. 2017 Jul-Aug:58(4):143-148. doi: 10.4103/nmj.NMJ_47_17. Epub
[PubMed PMID: 31057207]
[64]
Bajalan Z, Alimoradi Z, Moafi F. Nutrition as a Potential Factor of Primary Dysmenorrhea: A Systematic Review of Observational Studies. Gynecologic and obstetric investigation. 2019:84(3):209-224. doi: 10.1159/000495408. Epub 2019 Jan 10
[PubMed PMID: 30630172]
Level 1 (high-level) evidence
[65]
Ziaei S, Zakeri M, Kazemnejad A. A randomised controlled trial of vitamin E in the treatment of primary dysmenorrhoea. BJOG : an international journal of obstetrics and gynaecology. 2005 Apr:112(4):466-9
[PubMed PMID: 15777446]
Level 1 (high-level) evidence
[66]
Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. The Cochrane database of systematic reviews. 2001:(3):CD002124
[PubMed PMID: 11687013]
Level 1 (high-level) evidence